Kimberly-Clark
KMB
$104.28
+1.11%
Kimberly-Clark Corp. is a global manufacturer of essential consumer products, operating in the Household & Personal Products industry with a portfolio of leading brands including Huggies, Kleenex, Cottonelle, and Kotex. The company is a dominant player in the tissue and hygiene realm, deriving over half its sales from personal care and another third from consumer tissue products, while also serving the professional segment with workplace safety and sanitation solutions. The current investor narrative is heavily focused on the company's pending acquisition of Kenvue's consumer health portfolio slated for the second half of 2026, a major strategic move aimed at expanding its footprint, alongside debates around its ability to navigate inflationary pressures and defend market share in a competitive, slow-growth sector while maintaining its attractive dividend profile.…
KMB
Kimberly-Clark
$104.28
Related headlines
Investment Opinion: Should I buy KMB Today?
Rating & Thesis: KMB is a Hold. The stock presents a compelling value and income proposition but is burdened by near-term fundamental headwinds and execution risk, making it unsuitable for aggressive buying until revenue trends stabilize. The mixed analyst sentiment, with actions ranging from 'Sell' to 'Overweight', reflects this uncertainty.
Supporting Evidence: The forward P/E of 13.5x is historically and sector-wise cheap, and the 4.94% dividend yield is well-covered by $2.38B in annual FCF. However, these positives are counterbalanced by a -17.2% YoY revenue decline in Q4, significant margin compression (net margin down ~10 percentage points from 2024 peaks), and a high debt load (D/E of 4.77). The stock's -23.6% 1-year underperformance versus the SPY further underscores the market's skepticism.
Risks & Conditions: The thesis would upgrade to a Buy if quarterly revenue declines halt and show sequential improvement, or if the forward P/E compresses further below 12x. It would downgrade to a Sell if the dividend coverage deteriorates (payout ratio exceeds 100%) or if the Kenvue deal faces material regulatory or financing setbacks. Based on current data, the stock is fairly valued relative to its challenged growth profile but undervalued on a pure cash flow and yield basis.
Sign up to view all
KMB 12-Month Price Forecast
KMB is a classic 'show me' story trading at a distressed valuation. The near-term fundamentals are undeniably weak, with sharp revenue declines and margin pressure. However, the market has punished this severely, baking in low expectations as seen in the discounted P/E and high yield. The path forward hinges on stabilizing the core business; without that, the attractive yield is at risk. The Kenvue deal is a potential long-term catalyst but a near-term overhang. The stance would turn bullish on evidence of revenue stabilization (sequential growth), and bearish on a dividend cut warning or a major setback to the acquisition.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kimberly-Clark's 12-month outlook, with a consensus price target around $135.56 and implied upside of +30.0% versus the current price.
Average Target
$135.56
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$83 - $136
Analyst target range
Analyst coverage for Kimberly-Clark is limited, with only 6 analysts providing estimates, indicating it is a large-cap but potentially less-followed name within the staples sector. The consensus sentiment appears mixed to cautious, as evidenced by recent institutional ratings which include actions like 'Hold' from Deutsche Bank and TD Cowen, a 'Sell' from Citigroup, and an 'Overweight' from Piper Sandler, reflecting uncertainty around the company's growth trajectory and the integration of the pending Kenvue acquisition. The target price range implied by EPS estimates is wide, with a low EPS estimate of $8.98 and a high of $10.03, translating to a significant spread in potential valuations; the high target likely assumes successful cost management, stable margins, and accretive benefits from the Kenvue deal, while the low target likely prices in continued revenue declines, integration risks, and margin pressure. The limited number of analysts and the recent reiteration of neutral-to-negative ratings suggest a lack of strong bullish catalysts in the near term, contributing to the stock's depressed valuation and high dividend yield as investors await clearer signs of a fundamental turnaround.
Bulls vs Bears: KMB Investment Factors
The evidence currently tilts bearish, as fundamental deterioration in revenue and margins outweighs the stock's attractive valuation and dividend yield. The most critical tension in the investment debate is whether the historically cheap valuation and high yield adequately compensate for the severe top-line contraction and margin pressure, or if these challenges represent a secular decline that the pending Kenvue acquisition cannot reverse. The bear case is supported by concrete, worsening financials, while the bull case relies on a reversion to mean valuation and successful execution of a future strategic move.
Bullish
- Historically Cheap Valuation: KMB trades at a trailing P/E of 16.63x and a forward P/E of 13.50x, a significant discount to its historical multiples and likely below the broader consumer staples sector average. This compression, with the stock down 23.6% over the past year, suggests the market has priced in significant pessimism, creating a potential value opportunity.
- Strong Free Cash Flow & Dividend: The company generates robust free cash flow of $2.38 billion TTM, providing ample coverage for its substantial 4.94% dividend yield. With a payout ratio of 82.14%, the dividend appears sustainable, offering a defensive income stream while investors await a turnaround.
- Defensive, Low-Beta Profile: KMB's beta of 0.302 indicates it is approximately 70% less volatile than the broader market (SPY). This defensive characteristic makes it a potential safe haven during market downturns, as evidenced by its recent 5.41% 1-month gain while the SPY declined 0.08%.
- Strategic Kenvue Acquisition Pending: The pending acquisition of Kenvue's consumer health portfolio in H2 2026 represents a major strategic pivot to expand KMB's footprint. If executed successfully, it could provide a new, accretive growth vector for the otherwise mature business, though integration risks are high.
Bearish
- Severe Revenue Contraction: Q4 2025 revenue of $4.08B declined 17.21% YoY, continuing a sequential quarterly decline from $4.84B in Q1 2025. This indicates deep top-line pressure from volume declines, pricing normalization, and FX headwinds, challenging the core growth narrative.
- Margin Compression & Profitability Erosion: Net margin has compressed significantly, falling to 12.23% in Q4 2025 from 21.89% in Q3 2024. Gross margin of 35.91% and operating margin of 14.46% reflect ongoing inflationary cost pressures that the company has been unable to fully offset.
- High Financial Leverage: A debt-to-equity ratio of 4.77 indicates a highly leveraged balance sheet. This elevated leverage, combined with a tight current ratio of 0.75, increases financial risk, especially in a higher interest rate environment and ahead of a major acquisition.
- Persistent Negative Momentum: The stock is in a pronounced downtrend, trading 26% below its 52-week high and only 24% above its 52-week low. Its 1-year performance of -23.6% severely underperformed the SPY (+22.86%), signaling a lack of investor confidence and negative momentum.
KMB Technical Analysis
The stock is in a pronounced long-term downtrend, with a 1-year price change of -23.60%, significantly underperforming the broader market (SPY +22.86%). Currently trading at $102.29, the price sits just 24% above its 52-week low of $92.42 and 26% below its 52-week high of $137.46, positioning it in the lower quartile of its annual range, which suggests the stock is deeply oversold and may represent a value opportunity, though it also indicates persistent negative momentum and a lack of bullish catalysts. Recent short-term momentum shows a modest recovery, with a 1-month gain of 5.41% and a 3-month gain of 3.49%, which diverges positively from the severe 1-year downtrend; however, this nascent rebound must be viewed in the context of a -0.83% 6-month change, signaling the recovery is fragile and the stock remains in a broader consolidation phase below previous highs. Key technical support is clearly defined at the 52-week low of $92.42, while resistance lies near the 52-week high of $137.46; a sustained break below support could trigger another leg down, whereas a move above the recent February peak near $111 would be needed to signal a potential trend reversal. The stock's beta of 0.302 indicates it is approximately 70% less volatile than the SPY, which is typical for a defensive consumer staples name and suggests muted price swings relative to market gyrations.
Beta
0.30
0.30x market volatility
Max Drawdown
-35.3%
Largest decline past year
52-Week Range
$92-$137
Price range past year
Annual Return
-20.2%
Cumulative gain past year
| Period | KMB Return | S&P 500 |
|---|---|---|
| 1m | +8.7% | +1.5% |
| 3m | +5.6% | +13.4% |
| 6m | +2.7% | +10.9% |
| 1y | -20.2% | +24.5% |
| ytd | +2.8% | +10.0% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KMB Fundamental Analysis
Revenue growth is stagnant to slightly negative, with Q4 2025 revenue of $4.08 billion representing a -17.21% year-over-year decline, continuing a trend of sequential quarterly declines from $4.84B in Q1 2025 to $4.16B in Q2 and $4.13B in Q3; this trajectory indicates significant top-line pressure, likely from volume declines, pricing normalization, and foreign exchange headwinds, challenging the company's organic growth profile. Profitability remains intact but under pressure, with Q4 2025 net income of $499 million and a net margin of 12.23%, supported by a gross margin of 35.91% and an operating margin of 14.46%; however, margins have compressed from higher levels seen in 2024 (e.g., Q3 2024 net margin was 21.89%), reflecting inflationary cost pressures and the revenue decline, though the company continues to generate positive earnings. The balance sheet is highly leveraged with a debt-to-equity ratio of 4.77, indicating significant financial leverage, but the company maintains solid cash generation with trailing twelve-month free cash flow of $2.38 billion, providing ample coverage for its substantial dividend (payout ratio of 82.14%) and capital expenditures, while a current ratio of 0.75 suggests relatively tight liquidity, which is not uncommon for mature CPG firms with efficient working capital management.
Quarterly Revenue
$4.1B
2025-12
Revenue YoY Growth
-0.17%
YoY Comparison
Gross Margin
+0.35%
Latest Quarter
Free Cash Flow
$2.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KMB Overvalued?
Given a positive net income of $499 million in the latest quarter, the primary valuation metric is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 16.63x and a forward PE of 13.50x based on analyst estimates; the forward multiple being lower suggests the market anticipates earnings growth or recovery, though the negative PEG ratio of -0.84 implies the market does not view current growth prospects favorably relative to its earnings multiple. Compared to sector averages, Kimberly-Clark's trailing PE of 16.63x is likely at a discount to the broader consumer staples sector (which often trades in the low-20s), while its Price-to-Sales ratio of 1.95x and EV/Sales of 2.44x also appear reasonable for a stable, cash-generative business, indicating the market has priced in its growth challenges. Historically, the stock's own valuation has compressed significantly; its current trailing PE of 16.63x is near the bottom of its multi-year range, having fallen from levels above 20x and even 30x in recent years, suggesting the stock is at a historically cheap level, which could signal a value opportunity if fundamentals stabilize, but also reflects diminished growth expectations and investor skepticism about near-term prospects.
PE
16.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~114x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are pronounced. The company faces significant revenue pressure, with Q4 sales down 17.2% YoY, and profitability is eroding as net margins have halved from recent peaks. A debt-to-equity ratio of 4.77 indicates high financial leverage, which could constrain strategic flexibility and amplify earnings volatility. While strong free cash flow of $2.38B covers the dividend, the 82% payout ratio leaves limited room for error if earnings decline further.
Market & Competitive Risks center on valuation compression and strategic execution. Trading near multi-year lows, the stock's negative PEG ratio of -0.84 shows the market discounts its growth prospects. The pending Kenvue acquisition, while a potential catalyst, introduces massive integration and execution risk, potentially distracting management and straining the already leveraged balance sheet. As a defensive staple with a beta of 0.30, the stock also faces sector rotation risk if investors pivot away from value/income plays towards growth.
The Worst-Case Scenario involves a failure to stabilize core business revenues, coupled with a botched Kenvue integration that leads to significant write-downs and further margin compression. This could trigger a dividend cut, multiple compression, and a re-test of the 52-week low of $92.42. From the current price of $102.29, this implies a realistic downside of approximately -10%. A more severe bear case, factoring in a recessionary hit to consumer staples, could see the stock fall towards the $80s, representing a loss of over -20%.
FAQ
The key risks are, in order of severity: 1) Financial & Operational: Continued revenue decline (-17.2% YoY in Q4) and margin compression, threatening earnings and the dividend's coverage (82% payout ratio). 2) Balance Sheet: High financial leverage with a debt-to-equity ratio of 4.77, which could limit flexibility. 3) Strategic: Execution and integration risks associated with the pending Kenvue acquisition, a multi-billion dollar bet in an uncertain environment. 4) Market: Persistent negative momentum, with the stock down 23.6% over the past year, indicating a lack of catalyst to reverse sentiment.
The 12-month forecast is a range-bound outcome with a neutral bias. The base case (60% probability) sees the stock trading between $105 and $120, as revenue declines moderate and the stock is supported by its dividend yield. The bull case (25% probability) targets $125-$137, requiring a successful business stabilization and positive Kenvue deal sentiment. The bear case (15% probability) could see a re-test of the 52-week low near $92, driven by worsening fundamentals or acquisition setbacks. The most likely scenario is the base case, which assumes the current challenges persist but do not significantly worsen.
KMB appears undervalued on a historical and relative basis, but this discount is justified by its deteriorating fundamentals. Its trailing P/E of 16.63x and forward P/E of 13.50x are near multi-year lows and likely below the consumer staples sector average. The Price-to-Sales ratio of 1.95x is also reasonable. However, the negative PEG ratio of -0.84 signals the market sees no growth to support even this multiple. The valuation implies the market expects continued challenges, making the stock fairly valued relative to its near-term prospects but potentially deeply undervalued if management can execute a turnaround.
KMB is a good buy only for a specific type of investor: those seeking high, defensive income who can tolerate near-term price stagnation and fundamental uncertainty. With a 4.94% dividend yield and a forward P/E of 13.5x, it offers compelling value and income. However, with revenue declining 17.2% YoY and margins under pressure, it carries significant business risk. It is not suitable for growth-oriented investors. A patient income investor might find the current valuation an attractive entry point, but should be prepared for further volatility.
KMB is suitable only for long-term investment (minimum 3-5 year horizon). As a slow-growth, high-yield staple, it offers little catalyst for short-term trading, especially given its low beta of 0.30. The investment thesis is based on collecting the dividend while waiting for the Kenvue acquisition to be integrated and for potential operational improvements to materialize in the core business. Short-term traders would be frustrated by the stock's low volatility and lack of momentum. Long-term income investors can use time to their advantage, allowing the dividend to compound while hoping for a valuation recovery.
